Phospho-JAK2 (Y931) Antibody

What is the specificity of Phospho-JAK2 (Y931) Antibody?

Phospho-JAK2 (Y931) Antibody specifically detects endogenous levels of JAK2 protein only when phosphorylated at tyrosine residue 931. The antibody is generated using a synthesized peptide derived from human JAK2 encompassing the phosphorylation site of Tyr931 (amino acid range 906-955) . Specificity is typically confirmed through techniques such as phospho-peptide competition assays, where pre-incubation with the phosphorylated immunogen peptide blocks antibody binding, while the non-phosphorylated peptide does not affect detection . When selecting this antibody for experiments, researchers should verify that it has been validated against appropriate controls, including phosphatase-treated samples and JAK2-deficient cell lines.

What applications is Phospho-JAK2 (Y931) Antibody validated for?

Phospho-JAK2 (Y931) Antibody has been validated for multiple applications, with specific dilution recommendations for each technique:

These applications enable comprehensive analysis of JAK2 phosphorylation status across multiple experimental platforms .

What is the functional significance of JAK2 phosphorylation at Y931?

JAK2 undergoes phosphorylation at multiple tyrosine residues, with Y931 being one of several key regulatory sites. While Y1007/Y1008 in the activation loop are the most well-characterized phosphorylation sites, Y931 phosphorylation contributes to the regulation of JAK2 kinase activity .

JAK2 functions as a non-receptor tyrosine kinase involved in various processes including cell growth, development, differentiation, and histone modifications. It mediates essential signaling events in both innate and adaptive immunity . Phosphorylation at Y931 occurs alongside other sites during JAK2 activation in response to cytokine stimulation. The functional consequences of Y931 phosphorylation appear distinct from the activation loop phosphorylation, potentially contributing to fine-tuning of JAK2 signaling rather than serving as an on/off switch for kinase activity .

How should Phospho-JAK2 (Y931) Antibody be stored and handled?

To maintain optimal activity of the Phospho-JAK2 (Y931) Antibody, follow these storage and handling guidelines:

• Long-term storage: Store at -20°C for up to 1 year from the date of receipt

• Short-term storage: For frequent use, store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles which can degrade antibody quality

• The antibody is typically formulated in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Working dilutions should be prepared fresh and used within 24 hours

These storage conditions help preserve antibody specificity and sensitivity, ensuring consistent experimental results.

How can I validate the specificity of Phospho-JAK2 (Y931) Antibody in my experimental system?

Comprehensive validation of Phospho-JAK2 (Y931) Antibody specificity requires multiple approaches:

• Phosphatase treatment control: Treat half of your lysate with lambda phosphatase before immunoblotting. The signal should disappear in the treated sample.

• Phospho-peptide competition: Pre-incubate the antibody with phosphorylated Y931 peptide. This should block specific binding, while a non-phosphorylated peptide control should not affect detection .

• JAK2 inhibitor treatment: Treat cells with specific JAK2 inhibitors like ruxolitinib prior to analysis. Y931 phosphorylation should decrease in a dose-dependent manner .

• Stimulation experiments: Treat cells with known JAK2 activators such as interferon-γ, growth hormone, or erythropoietin to induce phosphorylation .

• Genetic approaches: Use JAK2-knockout or knockdown models as negative controls, or cells expressing JAK2 Y931F mutant which cannot be phosphorylated at this site .

A combination of these approaches provides robust validation across different experimental contexts, ensuring that observed signals genuinely represent phosphorylated JAK2 Y931.

What role does JAK2 Y931 phosphorylation play in resistance to JAK inhibitors?

JAK2 inhibitor resistance is an emerging challenge in treating JAK2-driven malignancies. While mutations in the JAK2 ATP binding site are common mechanisms of resistance to type I JAK2 inhibitors (ruxolitinib, fedratinib, lestaurtinib), the relationship between Y931 phosphorylation and inhibitor resistance involves complex regulatory mechanisms:

• Conformational effects: Y931 phosphorylation may stabilize JAK2 conformations that affect inhibitor binding. Unlike activation loop phosphorylation (Y1007/Y1008), Y931 is not directly in the ATP binding pocket but could influence protein dynamics .

• Resistance monitoring: Monitoring Y931 phosphorylation alongside other phosphorylation sites may help identify emerging resistance patterns in patients treated with JAK2 inhibitors .

• Type I vs. Type II inhibitors: Research indicates that type II JAK2 inhibitors like CHZ-868 may overcome some resistance mechanisms to type I inhibitors. Studying Y931 phosphorylation status could help elucidate differential sensitivities .

• HSP90 inhibition strategy: HSP90 inhibitors have shown efficacy against ruxolitinib-resistant JAK2 variants through JAK2 degradation mechanisms. This approach targets JAK2 protein stability rather than just kinase activity, potentially bypassing phosphorylation-dependent resistance mechanisms .

Y931 phosphorylation analysis could serve as a biomarker for monitoring treatment response and predicting resistance development in clinical settings.

What are the technical considerations for multiplexed analysis of JAK2 phosphorylation sites?

Analyzing multiple JAK2 phosphorylation sites simultaneously provides a comprehensive view of JAK2 activation status. Key technical considerations include:

• Antibody compatibility: When performing multiplexed immunoblotting, ensure antibodies are raised in different host species or use specialized systems for same-species antibodies. For Phospho-JAK2 (Y931) Antibody, which is typically rabbit-derived, pair with mouse antibodies for other phospho-sites .

• Stripping and reprobing protocols: If sequential probing is necessary:

  • Use mild stripping buffers (e.g., 0.2M glycine, pH 2.5)

  • Verify complete removal of primary antibody before reprobing

  • Start with the weakest antibody signal, progressing to stronger ones

  • Include loading controls on separate blots to avoid stripping artifacts

• Phosphorylation dynamics: Different JAK2 phosphorylation sites show distinct temporal patterns:

  • Y1007/Y1008 (activation loop): Rapid and strong phosphorylation upon stimulation

  • Y931: Often shows more sustained phosphorylation kinetics

  • Y221: Enhances kinase activity

  • Y570: Located in the JH2 inhibitory domain, may inhibit JAK2 activity

• Sample preparation: Phosphorylation is sensitive to:

  • Rapid dephosphorylation by endogenous phosphatases

  • Use phosphatase inhibitors (sodium orthovanadate, sodium fluoride) in lysis buffers

  • Maintain samples at 4°C throughout processing

  • Prepare fresh lysates whenever possible

• Quantitative approaches: Consider phospho-flow cytometry or mass spectrometry-based phosphoproteomics for more quantitative and comprehensive phosphorylation analysis across multiple sites simultaneously.

How can I optimize Phospho-JAK2 (Y931) Antibody for immunohistochemistry in patient-derived samples?

Optimizing Phospho-JAK2 (Y931) Antibody for patient-derived samples in IHC requires addressing several technical challenges:

• Fixation optimization:

  • Test different fixation protocols: 10% neutral buffered formalin is standard, but phospho-epitopes may require shorter fixation times (4-24 hours)

  • Consider testing ethanol-based fixatives which may better preserve phospho-epitopes

• Antigen retrieval methods:

  • Compare heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 8.0-9.0)

    • Optimize time and temperature (95-125°C for 10-30 minutes)

• Signal amplification systems:

  • Standard ABC (avidin-biotin complex) method

  • Polymer-based detection systems

  • Tyramide signal amplification for enhanced sensitivity

• Background reduction strategies:

  • Block endogenous peroxidase: 0.3% H₂O₂ in methanol for 10-30 minutes

  • Block endogenous biotin if using biotin-based detection

  • Optimize blocking with BSA, normal serum, commercial blockers

  • Test antibody dilutions broader than the recommended 1:100-1:300 range

• Validation controls:

  • Known positive tissue: Samples from cytokine-stimulated tissues

  • Negative controls: Include JAK2-negative tissues

  • Absorption controls: Pre-incubate antibody with phospho-peptide

  • Phosphatase controls: Treat section with lambda phosphatase

• Downstream analysis:

  • Develop standardized scoring systems for phospho-JAK2 positivity

  • Consider digital pathology approaches for quantification

  • Correlate with clinical outcomes and other biomarkers

Patience in optimization is crucial, as phospho-specific IHC typically requires more extensive validation than regular IHC protocols.

What experimental approaches are recommended for studying JAK2 Y931 phosphorylation dynamics in response to cytokine stimulation?

To investigate dynamic changes in JAK2 Y931 phosphorylation following cytokine stimulation, consider these methodological approaches:

• Time-course experiments:

  • Stimulate cells with relevant cytokines (IFN-γ, EPO, GH, leptin)

  • Collect samples at multiple timepoints (0, 5, 15, 30, 60, 120, 240 minutes)

  • Process all samples simultaneously for Western blot

  • Quantify phospho/total JAK2 ratios at each timepoint

• Dose-response relationships:

  • Treat cells with increasing concentrations of cytokines

  • Compare EC50 values for Y931 phosphorylation versus other sites (Y1007/Y1008)

  • Correlate with downstream STAT activation to establish signaling thresholds

• Live-cell imaging approaches:

  • Utilize FRET-based biosensors incorporating Y931-containing domains

  • Consider split-luciferase complementation assays

  • Phospho-specific nanobodies fused to fluorescent proteins

• Quantitative proteomics:

  • SILAC or TMT labeling for quantitative phosphoproteomics

  • Enrichment of phosphotyrosine peptides using anti-pTyr antibodies

  • Parallel reaction monitoring (PRM) mass spectrometry for targeted quantification of Y931 phosphopeptides

• Correlation with functional outcomes:

  • Measure STAT activation simultaneously (Western blot, EMSA, reporter assays)

  • Assess cellular outcomes (proliferation, differentiation, gene expression)

  • Use specific JAK2 inhibitors to establish causality

• Mathematical modeling:

  • Develop computational models incorporating Y931 phosphorylation

  • Use experimental data to refine and validate models

  • Predict system behavior under different stimulation conditions

These approaches together provide a comprehensive understanding of Y931 phosphorylation dynamics in physiological and pathological contexts.

How does JAK2 Y931 phosphorylation compare across different hematological malignancies?

JAK2 Y931 phosphorylation patterns vary across hematological malignancies, reflecting different pathogenic mechanisms:

• Myeloproliferative neoplasms (MPNs):

  • Polycythemia vera, essential thrombocythemia, and primary myelofibrosis often harbor JAK2 V617F mutations

  • These mutations lead to constitutive JAK2 activation and elevated phosphorylation at multiple sites

  • Y931 phosphorylation may serve as a biomarker for active JAK2 signaling and potential therapeutic response

• Acute lymphoblastic leukemia (ALL):

  • JAK2 rearrangements (JAK2r) are present in high-risk B-ALL

  • Fusion proteins like ATF7IP-JAK2 show altered phosphorylation patterns

  • Y931 phosphorylation status may provide insights into fusion protein activity and inhibitor sensitivity

• Immunohistochemical analysis of patient samples:

  • Differential Y931 phosphorylation levels can be assessed in bone marrow biopsies

  • Correlation with disease classification and treatment response

  • Potential prognostic indicator when combined with other molecular markers

• Inhibitor response prediction:

  • Y931 phosphorylation dynamics upon JAK2 inhibitor treatment

  • Correlation between persistent Y931 phosphorylation and clinical resistance

  • Potential for identifying patients who might benefit from alternative therapeutic approaches

Comparative analysis across malignancies provides insights into shared and distinct JAK2 activation mechanisms, potentially guiding therapeutic decisions.

What methods can detect JAK2 inhibitor resistance mutations and their impact on Y931 phosphorylation?

Detecting JAK2 inhibitor resistance mutations and their relationship to Y931 phosphorylation involves integrating multiple technical approaches:

• Genomic detection methods:

  • Sanger sequencing of JAK2 ATP/drug binding sites

  • Next-generation sequencing with deep coverage

  • Droplet digital PCR for sensitive detection of emerging mutations

  • Cell-based screening with ENU mutagenesis to identify potential resistance mutations

• Structural and computational approaches:

  • Molecular docking using Schrodinger Maestro software to predict how mutations affect inhibitor binding

  • Molecular dynamics simulations to assess effects on protein conformation

  • Impact of mutations on Y931 accessibility and phosphorylation potential

• Functional validation:

  • Site-directed mutagenesis to introduce identified mutations

  • Stable expression in Ba/F3 cells and assessment of cytokine-independent growth

  • Measurement of drug sensitivities using MTS-based viability assays

  • Comparison of Y931 phosphorylation levels between wild-type and mutant JAK2

• Phosphorylation analysis in resistant models:

  • Western blotting to compare phospho-Y931 levels in sensitive versus resistant cells

  • Assessment of whether Y931 phosphorylation persists despite inhibitor treatment in resistant cells

  • Correlation with activation of downstream STAT pathways

• Alternative therapeutic approaches:

  • Testing type II JAK2 inhibitors (e.g., CHZ-868) against resistant mutants

  • Evaluation of HSP90 inhibitors that promote JAK2 degradation

  • Y931 phosphorylation as a biomarker for response to alternative therapies

These methods collectively provide a comprehensive approach to understanding resistance mechanisms and developing strategies to overcome them.

How can Phospho-JAK2 (Y931) Antibody be utilized in precision medicine approaches for JAK2-driven diseases?

Implementing Phospho-JAK2 (Y931) Antibody in precision medicine frameworks for JAK2-driven diseases involves several strategic applications:

• Patient stratification:

  • Assess baseline Y931 phosphorylation in patient samples (bone marrow biopsies, peripheral blood)

  • Correlate with JAK2 mutation status (V617F, exon 12, etc.)

  • Develop phosphorylation thresholds that predict therapeutic response

  • Integrate with other biomarkers to create comprehensive predictive models

• Monitoring treatment response:

  • Serial measurement of Y931 phosphorylation during JAK2 inhibitor therapy

  • Early identification of biochemical resistance preceding clinical progression

  • Adaptive treatment protocols based on phosphorylation dynamics

• Minimal residual disease detection:

  • Sensitive detection of residual JAK2 activity in patients with clinical response

  • Multiparameter flow cytometry incorporating phospho-JAK2 (Y931) detection

  • Integration with molecular genetic markers of disease burden

• Resistance mechanism characterization:

  • Distinguish between different mechanisms of treatment failure

  • Genomic alterations versus epigenetic adaptations versus bypass pathway activation

  • Guide selection of alternative or combination therapies

• Combination therapy rational design:

  • Identify patients likely to benefit from JAK2 inhibitor + HSP90 inhibitor combinations

  • Rational sequencing of therapies based on phosphorylation dynamics

  • Development of phospho-JAK2 signatures that predict synergistic combinations

• Clinical trial design:

  • Enrichment of trials based on Y931 phosphorylation biomarker status

  • Use as pharmacodynamic biomarker in early-phase trials

  • Correlation of phosphorylation patterns with clinical outcomes

The implementation of these approaches requires standardized assays, validated cutoff values, and prospective clinical studies to establish the clinical utility of phospho-JAK2 (Y931) as a precision medicine biomarker.

What are common troubleshooting approaches for Phospho-JAK2 (Y931) Antibody in Western blot applications?

When working with Phospho-JAK2 (Y931) Antibody in Western blot, researchers may encounter several challenges. Here are methodological solutions:

• Weak or no signal:

  • Fresh lysate preparation: Phospho-epitopes are sensitive to degradation

  • Enhanced phosphatase inhibition: Use 1mM sodium orthovanadate, 5mM sodium fluoride, and 10mM β-glycerophosphate

  • Optimization of antibody concentration: Test wider dilution range (1:250-1:2000)

  • Extended primary antibody incubation: Overnight at 4°C may improve signal

  • Enhanced blocking: 5% BSA is preferable to milk for phospho-antibodies

  • Signal amplification: Consider using HRP-conjugated anti-rabbit polymer detection systems

• High background:

  • More stringent washing: Increase TBST wash steps (5-6 times, 10 minutes each)

  • Lower antibody concentration: Test higher dilutions

  • Alternative blocking agents: Switch between BSA, casein, or commercial blockers

  • Filter antibody solution: Remove aggregates that may cause non-specific binding

  • Freshly prepared buffers: TBST should be made fresh to maintain proper pH

• Multiple bands:

  • Specificity validation: Perform phospho-peptide competition assays

  • Denaturation conditions: Optimize SDS concentration and heating time/temperature

  • Resolution improvement: Use longer gels or gradient gels for better separation

  • JAK family cross-reactivity: Verify with JAK2-specific knockdown controls

• Inconsistent results:

  • Standardized stimulation protocol: Precise timing and concentrations of stimuli

  • Consistent sample processing: Standardize time from cell lysis to gel loading

  • Loading controls: Use total JAK2 on parallel blots (avoid stripping)

  • Positive controls: Include a sample known to contain phospho-JAK2 (Y931)

Implementing these technical optimizations ensures reliable and reproducible detection of Y931 phosphorylation across experimental conditions.

How can I quantitatively compare JAK2 Y931 phosphorylation levels across different experimental conditions?

Quantitative analysis of JAK2 Y931 phosphorylation requires rigorous methodological approaches for accurate comparisons:

• Western blot quantification:

  • Linear dynamic range determination: Perform dilution series to identify quantitative range

  • Normalization strategy: Always normalize to total JAK2 run on parallel blots

  • Digital image acquisition: Use cooled CCD camera systems rather than film

  • Software analysis: Use dedicated software (ImageJ, Image Studio, etc.) with background subtraction

  • Technical replicates: Minimum of three independent experiments for statistical validity

• ELISA-based quantification:

  • Sandwich ELISA using capture with total JAK2 antibody and detection with Phospho-JAK2 (Y931) Antibody

  • Standard curve generation using recombinant phosphorylated JAK2 protein

  • Absolute quantification of phosphorylation levels in pg/ml or ng/ml

  • High dilution (1:20000) optimized for ELISA applications

• Flow cytometry approaches:

  • Fixation/permeabilization optimization for intracellular phospho-epitopes

  • Median fluorescence intensity (MFI) measurements

  • Normalization to isotype controls and total JAK2 staining

  • Multi-parameter analysis correlating with other signaling markers

• Mass spectrometry-based quantification:

  • Targeted approaches: Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM)

  • Heavy-labeled synthetic phosphopeptide standards for absolute quantification

  • SILAC or TMT labeling for relative quantification across conditions

  • Data processing with Skyline or vendor-specific software

• Statistical analysis:

  • Appropriate statistical tests: ANOVA with post-hoc tests for multiple comparisons

  • Normality testing before parametric analysis

  • Non-parametric alternatives when appropriate

  • Effect size calculation in addition to p-values

  • Visualization with box plots or violin plots rather than simple bar graphs

These approaches enable robust quantitative comparisons that can detect subtle but meaningful differences in phosphorylation across experimental conditions.

How might JAK2 Y931 phosphorylation status impact the tumor microenvironment in JAK2-driven malignancies?

The relationship between JAK2 Y931 phosphorylation and the tumor microenvironment represents an emerging research frontier:

• Immune cell interactions:

  • JAK2 signaling in both malignant cells and immune populations

  • Y931 phosphorylation status in tumor-associated macrophages and T cells

  • Impact on cytokine production and immune cell recruitment

  • Potential biomarker for immunotherapy response in JAK2-driven malignancies

• Stromal cell crosstalk:

  • JAK2 activation in cancer-associated fibroblasts

  • Y931 phosphorylation in response to tumor-derived factors

  • Reciprocal signaling between malignant cells and stromal components

  • Dual targeting strategies addressing both compartments

• Methodological approaches:

  • Multiplex immunohistochemistry combining phospho-JAK2 (Y931) with immune markers

  • Single-cell phospho-proteomics of tumor microenvironment components

  • Spatial transcriptomics correlated with phospho-JAK2 status

  • Co-culture systems to model stromal-malignant cell interactions

• Therapeutic implications:

  • Impact of JAK2 inhibitors on the immune microenvironment

  • Rationale for combination with immune checkpoint inhibitors

  • Window of opportunity for immune activation during JAK2 inhibition

  • Biomarker potential of Y931 phosphorylation for predicting combinatorial approaches

This emerging area represents an important direction for translating molecular understanding of JAK2 signaling into more effective therapeutic strategies that address the complex ecosystem of JAK2-driven malignancies.

What role might JAK2 Y931 phosphorylation play in non-hematological diseases?

Beyond hematological malignancies, JAK2 Y931 phosphorylation may have significant implications in various pathological contexts:

• Inflammatory disorders:

  • Rheumatoid arthritis: JAK2 activation in synovial fibroblasts and infiltrating immune cells

  • Inflammatory bowel disease: Epithelial and immune JAK2 signaling

  • Psoriasis: JAK2 phosphorylation patterns in keratinocytes

  • Methodological approach: Analysis of Y931 phosphorylation in patient biopsies correlated with disease activity

• Metabolic diseases:

  • Obesity: JAK2 signaling in adipocytes and macrophages

  • Diabetes: β-cell JAK2 activation in response to cytokine-mediated stress

  • Non-alcoholic steatohepatitis: Hepatocyte JAK2 phosphorylation

  • Technical considerations: Optimization of phospho-JAK2 detection in metabolic tissues with high lipid content

• Neurological conditions:

  • Multiple sclerosis: JAK2 activation in microglia and infiltrating immune cells

  • Neurodegenerative diseases: Neuroinflammatory JAK2 signaling

  • Stroke: JAK2 phosphorylation in the ischemic penumbra

  • Methodological challenges: Preservation of phospho-epitopes in neural tissues

• Fibrotic diseases:

  • Pulmonary fibrosis: JAK2 signaling in myofibroblasts

  • Liver fibrosis: Hepatic stellate cell activation via JAK2 pathways

  • Renal fibrosis: JAK2 phosphorylation in tubular epithelial cells

  • Analytical approach: Co-localization of phospho-JAK2 (Y931) with fibrotic markers

• Cardiovascular pathologies:

  • Atherosclerosis: JAK2 activation in endothelial cells and foam cells

  • Cardiac hypertrophy: Cardiomyocyte JAK2 signaling

  • Pulmonary hypertension: JAK2 phosphorylation in pulmonary vascular remodeling

  • Technical optimization: Detection of phospho-JAK2 in vascular tissues

Studying Y931 phosphorylation across these contexts requires tissue-specific optimization of detection methods and correlation with functional outcomes to establish pathophysiological relevance.